In This Article:
On November 7, 2024, U.S. markets continued their upward trajectory following a post-election rally, with the S&P 500 and Nasdaq reaching record highs as the Federal Reserve announced a rate cut. In such buoyant market conditions, investors often look beyond established giants to explore opportunities in lesser-known areas like penny stocks. Although the term "penny stocks" may seem outdated, these smaller or newer companies still offer potential for growth when backed by strong financials.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
BAB (OTCPK:BABB) | $0.8479 | $5.86M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $161.01M | ★★★★★★ |
RLX Technology (NYSE:RLX) | $1.65 | $2.03B | ★★★★★★ |
LexinFintech Holdings (NasdaqGS:LX) | $3.91 | $590.24M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $69.71M | ★★★★★★ |
Better Choice (NYSEAM:BTTR) | $2.10 | $4.09M | ★★★★★★ |
Flexible Solutions International (NYSEAM:FSI) | $4.21 | $49.31M | ★★★★★★ |
PHX Minerals (NYSE:PHX) | $3.50 | $131.24M | ★★★★★☆ |
Zynerba Pharmaceuticals (NasdaqCM:ZYNE) | $1.30 | $65.6M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $1.10 | $97.13M | ★★★★★☆ |
Click here to see the full list of 747 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
BioAtla
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing specific and selective antibody-based therapeutics for treating solid tumor cancer, with a market cap of approximately $99.57 million.
Operations: BioAtla, Inc. has not reported any revenue segments.
Market Cap: $99.57M
BioAtla, Inc., with a market cap of approximately US$99.57 million, is a pre-revenue clinical-stage biopharmaceutical company focused on antibody-based cancer therapeutics. Despite its unprofitable status and high share price volatility, the company maintains a debt-free position with short-term assets exceeding liabilities. Recent developments include promising Phase 2 trial data for ozuriftamab vedotin in squamous cell carcinoma and a licensing agreement with Context Therapeutics potentially worth up to US$133.5 million in milestone payments and royalties. However, BioAtla faces challenges with less than one year of cash runway at current burn rates.
-
Unlock comprehensive insights into our analysis of BioAtla stock in this financial health report.
-
Review our growth performance report to gain insights into BioAtla's future.
Information Services Group
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Information Services Group, Inc. operates as a technology research and advisory company across the Americas, Europe, and the Asia Pacific with a market cap of $163.79 million.